Literature DB >> 3995447

The Vancouver Lymphadenopathy-AIDS Study: 1. Persistent generalized lymphadenopathy.

M T Schechter, W J Boyko, E Jeffries, B Willoughby, R Nitz, P Constance.   

Abstract

The Vancouver Lymphadenopathy-AIDS (acquired immune deficiency syndrome) Study is an ongoing prospective study of over 700 homosexual men attending six primary care practices in central Vancouver. A case-control study of risk factors for persistent generalized lymphadenopathy in homosexual men was conducted in five of the practices. The participants completed a questionnaire and underwent a complete physical examination at the time of enrollment and at a subsequent visit not less than 3 months later, and laboratory tests were performed after both visits. Persistent generalized lymphadenopathy was defined as the presence of lymph nodes greater than 1 cm in diameter at two or more extrainguinal sites for more than 3 months. Of the 519 patients who had completed both visits by February 1984, 126 (24%) were found to have the disease, and two controls without lymphadenopathy were frequency-matched on the basis of age and practice to each subject. More than 100 male sexual partners during one's lifetime, frequent receptive anal intercourse, a history of gonorrhea, use of illicit drugs and sexual contact in Los Angeles were identified as independent risk factors for persistent generalized lymphadenopathy. The similarity of these risk factors to those established for AIDS supports the hypothesis of a common etiology for the two diseases, and the high prevalence rate of persistent generalized lymphadenopathy further supports the hypothesis that AIDS is an uncommon response to a relatively common agent.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3995447      PMCID: PMC1346333     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  27 in total

1.  Estimability and estimation in case-referent studies.

Authors:  O Miettinen
Journal:  Am J Epidemiol       Date:  1976-02       Impact factor: 4.897

2.  Quantification of agreement in psychiatric diagnosis. A new approach.

Authors:  R L Spitzer; J Cohen; J L Fleiss; J Endicott
Journal:  Arch Gen Psychiatry       Date:  1967-07

3.  Relation between sexual practices and T-cell subsets in homosexually active men.

Authors:  R Detels; J L Fahey; K Schwartz; R S Greene; B R Visscher; M S Gottlieb
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

4.  Persistent generalized lymphadenopathy in homosexual men: clinical, pathological and immunologic characteristics.

Authors:  N J Gilmore; J F Prchal; S Jothy
Journal:  Can Med Assoc J       Date:  1983-11-01       Impact factor: 8.262

5.  Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma.

Authors:  R E Stahl; A Friedman-Kien; R Dubin; M Marmor; S Zolla-Pazner
Journal:  Am J Med       Date:  1982-08       Impact factor: 4.965

6.  Persistent diffuse lymphadenopathy in homosexual men: endpoint or prodrome?

Authors:  D I Abrams; B J Lewis; J H Beckstead; C A Casavant; W L Drew
Journal:  Ann Intern Med       Date:  1984-06       Impact factor: 25.391

7.  Kaposi's sarcoma in homosexual men. A seroepidemiologic case-control study.

Authors:  M Marmor; A E Friedman-Kien; S Zolla-Pazner; R E Stahl; P Rubinstein; L Laubenstein; D C William; R J Klein; I Spigland
Journal:  Ann Intern Med       Date:  1984-06       Impact factor: 25.391

8.  Longitudinal study of persistent generalised lymphadenopathy in homosexual men: relation to acquired immunodeficiency syndrome.

Authors:  U Mathur-Wagh; R W Enlow; I Spigland; R J Winchester; H S Sacks; E Rorat; S R Yancovitz; M J Klein; D C William; D Mildvan
Journal:  Lancet       Date:  1984-05-12       Impact factor: 79.321

9.  Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men.

Authors:  J J Goedert; M G Sarngadharan; R J Biggar; S H Weiss; D M Winn; R J Grossman; M H Greene; A J Bodner; D L Mann; D M Strong
Journal:  Lancet       Date:  1984-09-29       Impact factor: 79.321

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  9 in total

1.  Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic.

Authors:  Natalie N Kinloch; Daniel R MacMillan; Anh Q Le; Laura A Cotton; David R Bangsberg; Susan Buchbinder; Mary Carrington; Jonathan Fuchs; P Richard Harrigan; Beryl Koblin; Margot Kushel; Martin Markowitz; Kenneth Mayer; M J Milloy; Martin T Schechter; Theresa Wagner; Bruce D Walker; Jonathan M Carlson; Art F Y Poon; Zabrina L Brumme
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

2.  Human T-lymphotropic virus: exposure and prognosis.

Authors:  C L Soskolne; D Heyland; E Phillips
Journal:  CMAJ       Date:  1986-03-15       Impact factor: 8.262

3.  The Vancouver Lymphadenopathy-AIDS Study: 6. HIV seroconversion in a cohort of homosexual men.

Authors:  M T Schechter; W J Boyko; B Douglas; B Willoughby; A McLeod; M Maynard; K J Craib; M O'Shaughnessy
Journal:  CMAJ       Date:  1986-12-15       Impact factor: 8.262

4.  Relation of HTLV-III seropositivity and lymphadenopathy.

Authors:  E Jeffries; W J Boyko; B Willoughby; P D Constance; B Wiggs; M O'Shaughnessy; F R Sharp
Journal:  Can Med Assoc J       Date:  1985-07-15       Impact factor: 8.262

5.  Risk behaviours and HIV infection among men having sexual relations with men: baseline characteristics of participants in the Omega Cohort Study, Montreal, Quebec, Canada.

Authors:  A Dufour; M Alary; J Otis; R S Remis; B Mâsse; B Turmel; J Vincelette; R Parent; R Lavoie; R LeClerc
Journal:  Can J Public Health       Date:  2000 Sep-Oct

6.  Diagnostic utility of lymphocyte subset analysis in AIDS case finding.

Authors:  W J Boyko; M T Schechter; A MacLeod; B Douglas; M Maynard; R Sharp; B Wiggs
Journal:  CMAJ       Date:  1986-05-01       Impact factor: 8.262

7.  The Vancouver Lymphadenopathy-AIDS Study: 5. Antecedent behavioural, clinical and laboratory findings in patients with AIDS and HIV-seropositive controls.

Authors:  W J Boyko; M T Schechter; K J Craib; P Constance; R Nitz; S Fay; A McLeod; M O'Shaughnessy
Journal:  CMAJ       Date:  1986-10-15       Impact factor: 8.262

8.  The Vancouver Lymphadenopathy-AIDS Study: 7. Clinical and laboratory features of 87 cases of primary HIV infection.

Authors:  W J Boyko; M T Schechter; K J Craib; B Willoughby; B Douglas; P Sestak; W A McLeod; M O'Shaughnessey
Journal:  CMAJ       Date:  1987-07-15       Impact factor: 8.262

9.  Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic.

Authors:  Laura A Cotton; Xiaomei T Kuang; Anh Q Le; Jonathan M Carlson; Benjamin Chan; Denis R Chopera; Chanson J Brumme; Tristan J Markle; Eric Martin; Aniqa Shahid; Gursev Anmole; Philip Mwimanzi; Pauline Nassab; Kali A Penney; Manal A Rahman; M-J Milloy; Martin T Schechter; Martin Markowitz; Mary Carrington; Bruce D Walker; Theresa Wagner; Susan Buchbinder; Jonathan Fuchs; Beryl Koblin; Kenneth H Mayer; P Richard Harrigan; Mark A Brockman; Art F Y Poon; Zabrina L Brumme
Journal:  PLoS Genet       Date:  2014-04-24       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.